John joins VarmX from the position of CEO at Anthos Therapeutics, a clinical-stage biopharmaceutical company developing therapies for high-risk cardiovascular patients, including FXI inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback